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Abstract
Background: We previously showed that systemic administration of the atypical neuroleptic
clozapine in the rat altered a number of urodynamic variables and inhibited the external urethral
sphincter. Since clozapine acts at several receptor types both at the periphery and the central
nervous system, the site of action remained uncertain. Therefore, the purpose of this study was to
determine the effects of central administration of clozapine on the bladder and the external
urethral sphincter during cystometry and to examine differences in spinal versus supraspinal
administration. We extended our observations by delivering clozapine centrally in anesthetized rats
instrumented with either an intrathecal (L6-S1 spinal segment) or an intracerebroventricular
(lateral ventricle) catheter.
Results: Clozapine decreased micturition volume and increased residual volume possibly by acting
at a supraspinal site. Expulsion time and amplitude of the high frequency oscillations were reduced
by clozapine possibly by acting at a spinal site. Bladder capacity was increased after central clozapine
but probably due to a peripheral effect. Clozapine acting at spinal and supraspinal sites increased
pressure threshold. Contraction time and peak pressure were not affected by clozapine. The EMG
from the external urethral sphincter was also reduced following clozapine centrally and suggests a
spinal and a supraspinal site of action.
Conclusions: The results from the present study suggest that spinal and supraspinal central sites
mediate clozapine's action in inhibiting expulsion parameters and the external urethral sphincter of
the rat. Therefore, the reduction in the voiding efficiency observed after clozapine appears to be
mediated by spinal and supraspinal sites.
Background
Clozapine is a widely used atypical neuroleptic with affin-
ity for multiple receptors, including dopamine, serotonin,
alpha adrenergic, muscarinic and histaminergic receptors
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[1,2]. Although clozapine is effective in the treatment of
schizophrenia refractory to traditional antipsychotic med-
ication, it also has a number of significant side effects
ranging from the potentially fatal but rare agranulocytosis
to weight gain, constipation, seizures and urinary inconti-
nence [3]. Urinary problems have been reported in the
clinical literature with incontinence present in up to 44%
of patients [4] and enuresis in 27% of patients [5]. Since
clozapine has potent anti-muscarinic and anti-alpha
adrenergic effects [2], it has been proposed that peripheral
effects on the lower urinary tract might be responsible for
the micturition disturbances [6]. Incontinence has also
been reported following therapy with other atypical neu-
roleptics such as risperidone [7–9] and recently, olanzap-
ine [10].
We have previously shown that intravenous administra-
tion of clozapine to anesthetized rats [11,12] altered sev-
eral micturition parameters including a decreased amount
of volume voided per micturition and a concomitant in-
crease in the residual volume. In addition, clozapine also
inhibits the external urethral sphincter. Other, newer,
atypical neuroleptics (e.g. olanzapine and risperidone;
[13]) were also found to have similar effects but with dif-
fering potency compared to clozapine. Since risperidone
has little or no anti-muscarinic activity, a primary anti-
muscarinic peripheral effect may be ruled out as the cause
of micturition disturbances following risperidone admin-
istration, and suggest a possible central role for atypical
neuroleptics in regulating micturition.
The purpose of the present study was to determine the ef-
fects of clozapine administered centrally at two different
sites, spinal (L6-S1 spinal segments) vs. supraspinal (lat-
eral ventricle), on micturition and the external urethral
sphincter during cystometry in the anesthetized rat. By
limiting the application site to a specific area of the central
nervous system and comparing the results with our previ-
ous findings after systemic administration [12] it might be
possible to determine whether the effects of clozapine are
mediated at a central or peripheral level. Moreover, a com-
parison of the two central routes might indicate whether
the central effect involves spinal or supraspinal structures.
We report in this study that most of the effects of clozap-
ine on micturition are mediated by its central effects. Fur-
thermore, there are differences in spinal versus
supraspinal effects.
Results
Effects of central administration of clozapine on urody-
namic parameters during single cystometry (Table 1I)
Figures 1 and 2 show representative examples of the ef-
fects of clozapine on single cystometry in anesthetized rats
after intrathecal (i.t.; L6-S1 spinal segment) and intracere-
broventricular (i.c.v.; lateral ventricle) administration, re-
spectively.
Bladder capacity was increased by clozapine given i.t. or
i.c.v. only at the highest dose tested (Fig 1G; 2G). After 50
nmoles of clozapine i.t. the bladder capacity was 0.47 ±
0.09 ml, compared to 0.29 ± 0.027 ml after vehicle ad-
ministration (Fig 3A). Similarly, after 50 nmoles of cloza-
pine i.c.v the bladder capacity was 0.51 ± 0.11 ml,
compared to 0.25 + 0.027 ml after vehicle administration
(Fig 3A).
Table 1: 1. Effects of intrathecal (L6/S1 spinal level) administration increasing doses of clozapine on urodynamic and EMG parameters 
in anesthetized rats. Values are Mean ± S.E.M.
Urodynamic parameters EUS EMG parameters
Dose
(nmoles)
BC
(ml)
MV
(ml)
RV
(%)
PT
(mm Hg)
ct
(sec)
PP
(mm Hg)
ET
(sec)
HFO
(mm Hg)
Phase 1
(%)
Phase 2
(%)
Phase 3
(%)
Burst
Amp. (%)
Control 0.29
(± 0.04)
0.18
(± 0.022)
34
(± 7.5)
3.4
(± 0.46)
16.9
(± 1.32)
13.1
(± 0.82)
2.4
(± 0.30)
1.5
(± 0.10)
100 100 100 100
0.5 0.30
(± 0.02)
0.17
(± 0.018)
43
(± 4.1)
3.3
(± 0.79)
17.0
(± 2.00)
13.3
(± 1.20)
1.9
(± 0.55)
1.3
(± 0.26)
98
(± 10.3)
89
(± 26.9)
116
(± 12.0)
84
(± 17.0)
5.0 0.32
(± 0.06)
0.11**
(± 0.031)
69**
(± 6.2)
3.3
(± 0.49)
22.1
(± 1.49)
12.3
(± 0.66)
0.7**,a
(± 0.46)
0.4**,b
(± .23)
91
(± 20.0)
37*
(± 24.0)
94.7
(± 21.8)
32**,a
(± 20.5)
50 0.47**
(± 0.09)
0.08**
(± 0.019)
79**
(± 4.3)
6.0**
(± 0.86)
21
(± 3.39)
13.6
(± 0.72)
0.9*
(± 0.93)
0.5**
(± 0.19)
93
(± 24)
40*
(± 14.0)
72
(± 14.8)
66
(± 22.2)BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/6
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Micturition volume was significantly decreased after 5.0
and 50 nmoles of clozapine i.t. (Fig 3B) to 0.11 ± 0.031
and 0.08 ± 0.019 ml, respectively compared to 0.18 ±
0.022 ml after vehicle. In the case of intracerebroventricu-
lar administration, 0.5 nmoles of clozapine decreased the
micturition volume to 0.11 ± 0.02 ml compared to 0.16 ±
0.018 ml after vehicle (Fig 3B). The effect of 0.5 nmoles of
clozapine i.c.v. on micturition volume was significantly
different from the effect of the same dose given i.t. Further
reductions in micturition volume were observed after 50
nmoles of clozapine i.c.v.
Residual volume was significantly increased after 5.0 and
50 nmoles of clozapine i.t. to 69 ± 6.2% and 79 ± 4.3%,
compared to 34 ± 7.5% after vehicle administration (Fig
3C). Clozapine i.c.v. resulted in a significant increase in
the residual volume at all doses, including 0.5 nmoles. Af-
ter 0.5 nmoles i.c.v. the residual volume was 54 ± 8.5%
compared to 33 ± 7.4% after vehicle. This residual volume
was not significantly different from the one observed after
the same dose i.t. Larger doses of clozapine i.c.v. resulted
in further increases in the residual volume to 62 ± 3.8 and
80 ± 5.2% after 5.0 and 50 nmoles, respectively.
Clozapine i.t. or i.c.v caused an increase in the pressure
threshold only at the highest doses tested (Fig 1G; 2G;
4A). After 50 nmoles i.t. the pressure threshold was 6.0 ±
0.86 compared to 3.4 ± 0.46 mm Hg after vehicle, whereas
after i.c.v. administration the same dose increased the
pressure threshold to 7.2 ± 1.46 mm Hg compared to 2.9
± 0.29 mm Hg after vehicle.
Clozapine i.t. or i.c.v had no effect on either peak pressure
or contraction time in the range of doses tested (Fig
4B,5A) in this study.
Expulsion time was significantly decreased by clozapine at
5.0 and 50 nmoles either i.t. or i.c.v (Fig 5B). After vehicle
i.t. the expulsion time was 2.4 ± 0.3 sec, which decreased
to 0.7 ± 0.46 and 0.9 ± 0.93 sec after 5 and 50 nmoles i.t.
Similarly, after vehicle i.c.v the expulsion time was 3.0 ±
0.28 sec and 5.0 and 50 nmoles of clozapine i.c.v de-
creased it to 1.8 ± 0.35 and 1.3 ± 0.39 sec, respectively. The
effect of 5.0 nmoles of clozapine i.t. on the expulsion time
was significantly different from the effect observed after
i.c.v administration of this dose (Fig 5B).
Clozapine also decreased the amplitude of (and in some
animals even abolished) the high frequency oscillations
(HFO) after i.t. administration (Fig 1; 5C). After 5.0
nmoles of clozapine the HFO were 0.4 ± 0.23 compared
to 1.5 ± 0.1 mm Hg after administration of vehicle. In 4 of
the 6 animals in this group, 5 nmoles of clozapine i.t.
abolished the HFO. The reduction in amplitude observed
at this dose after i.t. administration of significantly differ-
ent from the effects observed after the same dose i.c.v. (Fig
5C). A greater dose of clozapine did not cause a larger ef-
fect although the amplitude of the HFO after 50 nmoles
of clozapine i.t. was still significantly reduced (0.5 ± 0.19
mm Hg) when compared to vehicle administration. Cloz-
apine i.c.v decreased the amplitude of the HFO only at 50
nmoles (0.6 ± 0.2 mm Hg compared to 1.6 ± 0.11 mm Hg
after vehicle administration; Fig 2), and the HFO were
abolished in only 1/6 of the animals in this group.
Table 2: 2. Effects of intracerebroventricular (Lateral ventricle) admnistration of increasing doses of clozapine on urodynamic and EMG 
parameters in anesthetized rats. Values are Mean ± S.E.M.
Urodynamic parameters EUS EMG parameters
Dose
(nmoles)
BC
(ml)
MV
(ml)
RV
(%)
PT
(mm Hg)
CT
(sec)
PP
(mm Hg)
ET
(sec)
HFO
(mm Hg)
Phase 1
(%)
Phase 2
(%)
Phase 3
(%)
Burst
Amp. (%)
Control 0.25
(± 0.027)
0.16
(± 0.018)
33
(± 7.4)
2.9
(± 0.29)
19.4
(± 1.5)
12.4
(± 0.46)
3.0
(± 0.28)
1.6
(± 0.11)
100 100 100 100
0.5 0.26
(± 0.026)
0.11*,b
(± 0.02)
54*
(± 8.5)
3.6
(± 0.30)
21.6
(± 3.0)
12.0
(± 0.90)
2.0
(± 0.33)
1.4
(± 0.19)
117
(± 9.4)
68*
(± 13.9)
95
(± 4.7)
101
(± 7.0)
5.0 0.30
(± 0.022)
0.11*
(± 0.019)
62**
(± 3.8)
3.3
(± 0 44)
22.2
(± 25)
12.6
(± 0 73)
1.8*
(± 0.35)
1.3
(± 0.07)
128
(+15 1)
54**
(± 8.4)
101
(± 10.0)
94
(± 5.5)
50 0.51**
(± 0.11)
0.084**
(± 0.014)
80**
(± 5.2)
7.2**
(± 1.46)
18.7
(± 1.9)
13.6
(± 0.34)
1.3**
(± 0.39)
0.6**
(± 0.20)
62*
(± 14.9)
26**
(± 9.9)
50*
(± 14.9)
65*
(± 17.2)
* p < 0.05 compared to control; ** p < 0.01 compared to control; a p < 0.05 compared to same dose, different route; b p < 0.01 compared to same 
dose, different routeBMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/6
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Figure 1
Representative traces of the effects of increasing dose of clozapine administered intrathecally (over the L6/S1 spinal segments)
on the cystometrogram and external urethral sphincter of anesthetized rats (n = 6). Top panel shows bladder pressure during
filling (0.11 ml/min) while bottom panel shows the integrated EMG recorded from the external urethral sphincter. Panels A and
B also show some of the urodynamic parameters measured during cystometry: BC = amount of fluid infused into the bladder
to elicit a contraction; PT = pressure at which contraction begins; PP = peak pressure during contraction; CT = contraction
time; HFO = high frequency oscillations recorded during expulsion; ET = time between peak pressure and end of high fre-
quency oscillations. The EMG activity was examined by dividing the contraction into 3 phases [19]: a contraction phase (Phase
1); an expulsion phase (Phase 2); a closing phase (Phase 3). A) Cystometrogram (CMG) following administration of vehicle
(saline) intrathecally. (B) Expanded time scale shows the HFO and the concomitant bursting pattern in the EUS EMG. C & D)
0.5 nmoles of clozapine i.t. does not have an effect on the CMG or the EUS EMG. E & F) 5 nmoles of clozapine i.t. abolished the
HFO (4/6 rats) and the bursting pattern in the EUS EMG. G & H) 50 nmoles of clozapine i.t. increased the bladder capacity and
also abolished the HFO and the bursting pattern in the EUS EMG of some rats (2/6). Unstable, non-voiding contractions were
occasionally seen following clozapine administration and preceding the final voiding contraction (1C; 1G). Calibration bar:
A,C,E,G = 1 min; B,D,F,H = 1 sec.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/6
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Figure 2
Representative traces of the effects of clozapine administered intracerebroventricularly (lateral ventricle) on the cystometro-
gram and activity of the external urethral sphincter of anesthetized rats. A & B) CMG after giving saline i.c.v. C & D) 0.5 nmoles
of clozapine i.c.v. did not show appreciable effects on the CMG or the EUS EMG. E & F) CMG after 5 nmoles of clozapine i.c.v.
Note a reduction in expulsion time and the amplitude of the HFO. G & H) 50 nmoles of clozapine i.c.v. increased the bladder
capacity. However, the HFO are still present although reduced. In none of the rats were the HFO abolished by clozapine i.c.v
contrasting the effects observed after spinal administration (Fig. 1). Non-voiding contractions are observed in this animal prior
to the final voiding contraction (2G). Calibration bar: A, C,E,G = 1 min; B,D,F,H = 1 sec.BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/6
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Effects of central administration of clozapine on the activ-
ity of the external urethral sphincter during single cystom-
etry (Table 1I)
Clozapine i.t. did not have an effect on the activity of the
EUS during Phase 1 (the rising phase during a contrac-
tion), and only the highest dose of clozapine i.c.v (50
nmoles) was found to decrease the activity of the EUS (Fig
6A) to 62 ± 14.9% of that seen during administration of
vehicle.
Phase 2 of the EUS EMG (occurring during the time of
HFO) was decreased by clozapine either i.t or i.c.v. 5 and
50 nmoles of clozapine i.t. decreased the EMG to 37 ± 24
and 40 ± 14% of that observed during administration of
vehicle, respectively (Fig 6B). In fact, in 4/6 animals, 5.0
nmoles of clozapine i.t. abolished the bursting pattern of
the EMG observed during phase 2 (Fig 1F). Clozapine ad-
ministered i.c.v at a dose of 0.5 nmoles decreased the EUS
EMG to 68 ± 13.9% of the activity observed after vehicle
administration (Fig 6B). Larger doses (5 and 50 nmoles)
of clozapine i.c.v further reduced the EUS activity during
this phase to 54 ± 8.4% and 26 ± 9.9%. Clozapine i.c.v,
however, was not observed to abolish the bursting pattern
during this phase (Fig 2), except in 1/6 animals.
Phase 3 of the EUS EMG (recorded during the falling
phase of a bladder contraction) was not affected by cloza-
pine administered intrathecally (Fig 6C). However, the
largest dose of clozapine given i.c.v (50 nmoles) decreased
the activity to 50 ± 14.9% of the activity observed during
vehicle administration.
Finally, the amplitude of the bursts observed during phase
2 in the EUS EMG were decreased to 32 ± 20.5% by 5.0
nmoles of clozapine i.t. (Fig 6D). A similar dose of cloza-
pine i.c.v had no effect. However, 50 nmoles of clozapine
i.c.v. decreased the amplitude of the bursts to 65 ± 17.2%
of that observed during vehicle administration.
Discussion
In the present experiments, central application of clozap-
ine (intrathecally over the L6/S1 spinal segments or in-
tracerebroventricularly into the lateral ventricle) resulted
in a number of changes in the urodynamic parameters of
anesthetized rats. The major effect of clozapine was to de-
crease the voiding efficiency of the bladder by inhibiting
expulsion parameters, such as micturition volume, resid-
ual volume and expulsion time. In addition, the activity of
the EUS also decreased upon central application of cloza-
pine. One problem in delivering substances centrally is
the possibility that peripheral spread may confound the
results. Since clozapine crosses the blood-brain barrier
readily [14], the maximum dose selected in the present ex-
periment was restricted to the first appearance of a de-
crease in blood pressure as an indication of possible
Figure 3
Effects of increasing doses of clozapine administered intrath-
ecally (i.t.) or intracerebroventricuarly (i.c.v.) on bladder
capacity, micturition volume and residual volume. For com-
parison purposes, the effects of intravenous admnistration of
clozapine (data from [12]) are also shown. Doses are pre-
sented in a log scale, with vehicle marked as V for the results
of the present experiments, and (V) for vehicle in the i.v.
doses. A) Bladder capacity increased only after 50 nmoles of
clozapine either i.t. or i.c.v.; B) Micturition volume decreased
after clozapine i.t. or i.c.v. However, 0.5 nmoles of clozapine
i.c.v. significantly reduced the micturition volume and this
effect was also significantly different from that obtained after
the same dose i.t. C) Residual volume was increased by cloz-
apine i.t. or i.c.v. All doses of clozapine i.c.v. produced signifi-
cant increases in the residual volume, whereas only 5 and 50
nmoles i.t. produced significant results. * = p < 0.05; ** = p <
0.01; # = p < 0.05 when compared to the effects of the same
dose, different route.
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peripheral alpha 1 antagonism due to peripheral leakage.
We compared the effects obtained in the present study
against those observed previously after intravenous ad-
ministration [12] expecting that central effects would re-
quire significantly less application of clozapine than
systemic administration. We considered a minimum dif-
ference of 10×  magnitude in the central vs. peripheral
dose that elicited a significant effect as an indication of
possible central action. Our doses of 0.5, 5 and 50 nmoles
of clozapine correspond to serum levels of 8, 80 and 800
ng/ml (assuming a blood volume of 8% of body weight)
and are in the range of therapeutic levels (260–387 ng/ml
[5,15]).
A second problem in administering a substance at a par-
ticular central location is that of redistribution to other
parts of the central nervous system. Since application of a
substance at the lumbosacral spinal level may travel to the
brain after some time and vice versa, we established two
criteria to help determine a possible central site of action:
1) the first dose to elicit a significant effect by either i.t. or
i.c.v administration; 2) significant differences at the same
dose but different routes (i.t. vs i.c.v).
Figure 7 is a summary of our findings when interpreted in
light of the criteria stated above for determining (a) cen-
tral vs peripheral effects and (b) spinal vs supraspinal site
of action. The effects are presented as percent change over
the control (vehicle) dose, for each of the central routes in
the present experiment and our previously reported find-
ings for systemic administration [12]. Theses changes are
plotted at the dose (mg/kg) that first yielded significant re-
sults. The route that we consider most likely to be the site
of action for clozapine is italicized.
Bladder capacity was increased to a similar degree by an
equivalent dose of clozapine, regardless of route (Fig 7A;
3A), making a determination of most likely site of action
difficult. Given that the peripheral effects at low doses
were similar to the effects after the highest central dose of
clozapine (by either route) it appears likely that this effect
is due to peripheral actions of clozapine. Bladder capacity
was reported to increase following i.c.v. administration of
muscarinic antagonist (atropine [16]) or i.t. alpha2 antag-
onists (yohimbine [17]; atipemazole [18]). Given clozap-
ine's strong affinity for muscarinic and alpha2 receptors
[2] it is possible that central effects are also contributing
to the increase in bladder capacity.
Micturition volume, on the other hand, showed a reduc-
tion after smaller doses of clozapine i.c.v or i.t. when com-
pared to the i.v. dose (Fig 7B;3B). Therefore, central effects
of clozapine in controlling micturition volume are likely.
Furthermore, when comparing the effects of i.t. vs. i.c.v
administration, a 5 nmoles dose of clozapine i.c.v. elicited
a reduction in micturition volume that was significantly
greater from the effects observed after the same dose i.t.
(Fig. 3B). Therefore, supraspinal effects of clozapine in
regulating micturition volume are likely with spinal ef-
fects perhaps contributing. Clozapine i.t. also decreased
the micturition volume, however the dose that first
showed a significant effect was higher than the i.c.v. but
smaller than the i.v. dose. Spinal antagonism of either
alpha1 or alpha2 adrenergic receptors was reported to in-
crease micturition volume [17] in anesthetized rats. How-
ever, intrathecal atipamezole (alpha2 antagonist)
Figure 4
Effect of clozapine i.t. or i.c.v on pressure threshold and peak
pressure. Data from intravenous administration [12] are
shown for comparison. A) Pressure threshold increased only
after the highest dose (50 nmoles) of clozapine either i.t. or
i.c.v.; B) Clozapine i.t. or i.c.v. had no effect on the peak pres-
sure. V= vehicle administration (saline) for i.t. or i.c.v. groups;
(V) = vehicle administration for i.v. group. * = p < 0.05; ** = p
< 0.01
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increased residual volume in awake rats [18]. Therefore, it
is difficult to interpret clozapine's effects on micturition
volume in terms of spinal alpha adrenoceptor antagonism
and possibly the supraspinal effects predominate.
Clozapine given i.t. or i.c.v. also increased the residual
volume (Fig 7C; 3C). Since the effects were observed at
doses that were lower than those after i.v. administration,
a peripheral effect of clozapine to increase residual vol-
ume appears unlikely. The smallest dose of clozapine giv-
en i.c.v. (0.5 nmoles) increased residual volume to 160%
(Fig 7C), suggesting that supraspinal effects predominate
with possible contributing effects from spinal sites. Ishiu-
ra et al. [16] reported a decrease in voiding efficiency
(comparable to an increase in residual volume) following
atropine i.c.v. or i.t. suggesting that muscarinic receptors
at supraspinal and spinal sites are involved and may ac-
count for our effects after clozapine i.t. or i.c.v. A decrease
in residual volume has been reported following spinal an-
tagonism of alpha2 receptors with yohimbine [17] but ati-
pamezole produced an increase in the residual volume
[18], similar to our findings with clozapine i.t.
Clozapine increased pressure threshold after i.c.v. or i.t.
administration only after 50 nmoles (Fig 7D; 4A). It
should be noted that both central doses were at the range
observed to result in cardiovascular changes and therefore
the possibility of peripheral leakage of clozapine must be
considered. Still the effective central doses are approxi-
mately 14×  less than the first dose observed to produce
significant results intravenously, and suggests a possible
central site of action.
Peak pressure was not changed by clozapine after either
route in the present study after central administration,
consistent with our findings afer intravenous administra-
tion [12]. Ishiura et al. [16] reported a decrease in maxi-
mal voiding pressure (equivalent to our peak pressure)
after atropine i.v., i.c.v or i.t. in awake rats undergoing
continuous cystometry. Given that clozapine has a rela-
tively high affinity for muscarinic receptors [1,2] it is sur-
prising that we have not seen an effect on peak pressure.
Clozapine, and also olanzapine [11,13] were able to de-
crease the contraction amplitude after electrical stimula-
tion of the pelvic nerve. Since the contraction pressures
observed during cystometry were smaller than those ob-
served after electrical stimulation of the pelvic nerve (and
against a closed urethra) it is possible that the antimus-
carinic effects of clozapine on bladder contraction pres-
sure are not detected because during cystometry maximal
bladder pressures are not necessary for emptying.
Contraction time was not affected by clozapine i.c.v or i.t.
(Table 1 and 2; Fig 5A) however it was clearly decreased
after intravenous administration [12]. Therefore, we sus-
Figure 5
Effect of clozapine i.t. or i.c.v. on contraction time, expulsion
time and amplitude of the high frequency oscillations (HFO).
Data from intravenous administration of clozapine [12] are
presented for comparison. A) Contraction time was not
affected by clozapine i.t. or i.c.v.; B) Expulsion time was
decreased by both clozapine i.t. or i.c.v. However, 5 nmoles
of clozapine i.t. resulted in a greater reduction in expulsion
time than the same dose given i.c.v. Only the highest dose
(50 nmoles) resulted in a decrease in the expulsion time
when given i.c.v. C) The amplitude of the HFO was signifi-
cantly reduced by 5 and 50 nmoles ofclozapie i.t. but only by
50 nmoles of clozapine i.c.v. The effect of 5 nmoles of clozap-
ine i.t. was significantly different from the same dose given
i.c.v. V= vehicle administration (saline) for i.t. or i.c.v. groups;
(V) = vehicle administration for i.v. group. * = p < 0.05; ** = p
< 0.01; # = p < 0.05 when compared to the effects of the
same dose, different route.
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pect that solely peripheral effects may explain the effects
of clozapine on contraction time. Antimuscarinic agents
have been show to decrease contraction time (e.g. atro-
pine [19]) and since clozapine has high affinity for mus-
carinic receptors it is likely that peripheral anti-muscarinic
effects of clozapine are responsible for the reduction in
contraction time after systemic administration.
Expulsion time was reduced by clozapine after i.t. or i.c.v.
administration at much smaller doses than were observed
to produce similar results i.v. (Fig 7E; 5B). Therefore, cen-
tral effects of clozapine are likely responsible for the re-
duction in expulsion time. Since the intrathecal effects
were greater than those observed after i.c.v. administra-
tion it is possible that a spinal action predominates with
possible contribution from supraspinal sites.
The amplitude of the high frequency oscillations observed
during the expulsion time in the rat micturition cycle
[20,21] was reduced by clozapine i.t. at a dose of 5 nmoles
(Fig 8F). This dose was 10×  smaller than the first i.c.v.
dose observed to have a significant effect and approxi-
Figure 6
Effects of clozapine i.t. or i.c.v. on the EMG recorded from the EUS during cystometry in anesthetized rats. Data from i.v.
administration of clozapine [12] are presented for comparison. A) Clozapine i.t. had no effect on the integrated EMG recorded
during phase 1 of the contraction. Only the highest dose of clozapine (50 nmoles) i.c.v. decreased the EMG during this phase to
62%; B) Clozapine i.t. or i.c.v. decreased the integrated EMG during phase 2 of the contraction. All doses of clozapine i.c.v. sig-
nificantly reduced the EMG whereas only 5 and 50 nmoles i.t. resulted in significant reductions. C) Only the highest dose of
clozapine i.c.v (50 nmoles) decreased the EMG during this phase of the contraction. Clozapine i.t. had no effects. D) The ampli-
tude of the individual bursts of EMG occurring during phase 2 of the contraction were reduced by clozapine i.t and i.c.v. How-
ever, 5 nmoles of clozapine i.t. produced a reduction of EMG that was significantly different from the effects of the same dose
given i.c.v. Only the highest dose (50 nmoles) was effective in reducing the EMG when administered i.c.v. V= vehicle administra-
tion (saline) for i.t. or i.c.v. groups; (V) = vehicle administration for i.v. group. * = p < 0.05; ** = p < 0.01; # = p < 0.05 when
compared to the effects of the same dose, different route.
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Figure 7
Summary of the effects of clozapine given i.t., i.c.v. or i.v. (data from [12]) on urodynamic parameters and the activity of the EUS during cystometry in anesthetized rats. The first
dose to yield a significant effect has been plotted for all 3 routes. Doses have been converted to mg/kg for ease of comparison. Peak pressure data are not shown since no signif-
icant differences were found with clozapine after any route. A) Bladder capacity is increased to a similar extent by comparable doses of clozapine, regardless of the route. There-
fore, a peripheral effect may be predominating. In the case of micturition volume (B) and residual volume (C), both clearly show a central effect since the first dose to yield a
significant effect is 142×  smaller than the i.v. dose. Both of these parameters show a possible supraspinal site of action. D) Pressure threshold increased only after the highest
dose of clozapine i.c.v or i.t., however, that dose was still 14×  smaller than the first dose i.v., suggesting a possible central effect. E) Expulsion time shows a 142×  difference
between the central dose and the peripheral dose. In addition, intrathecal administration shows a larger effect than after i.c.v., suggesting a possible spinal site of action. F) The
effect of clozapine on the amplitude of the HFO appears to be mediated by a spinal site. G) Phase 1 of the EMG was decreased after equivalent doses of clozapine i.v. or i.c.v.
Intrathecal administration had no effect. H) Phase 2 of the EMG (where the bursting occurs) clearly showed a central effect since a much smaller dose (142× ) was required to
produce an effect. In addition, the reduction after i.c.v. was greater than after i.t. therefore suggesting a possible supraspinal site of action. I) Phase 3 of the EMG was not affected
by clozapine intrathecally. Only the highest dose of clozapine given i.c.v decreased the EMG during this phase. That dose was 14×  smaller than the first dose to produce a signif-
icant effect after i.v. administration suggesting a possible supraspinal site of action. J) The amplitude of the individual bursts during phase 2 of the EMG was decreased by central
effects of clozapine at smaller doses than those observed i.v. Also, the intrathecal administration was much more effective in reducing the amplitude (abolished in 4/6) animals,
suggesting a possible spinal site of action.
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mately 142×  smaller than the first i.v. dose to show a sig-
nificant effect. Therefore, a spinal site mediating the
effects of clozapine on the amplitude of high frequency
oscillations appears likely. Previous results [12] suggest
that D2 receptors modulate the amplitude of the HFO,
since raclopride (selective D2 antagonist) decreased the
amplitude of the HFO by 30%.
In addition to clozapine's effects on urodynamic parame-
ters, the EMG recorded from the external urethral sphinc-
ter also showed changes after clozapine i.t. or i.c.v. The
EMG during phase 1 of the contraction only showed a re-
duction after the largest dose of clozapine i.c.v.. This dose
is equivalent to our lowest dose i.v. and in fact all doses
i.v. previously showed a significant reduction [11]. In-
trathecal administration had no effect on the EMG at
phase 1.
The EMG during phase 2, corresponding to the period of
high frequency oscillations was decreased by clozapine af-
ter i.t. or i.c.v administration at doses that were much low-
er than those necessary to produce an effect after i.v.
Therefore, the effects of clozapine in reducing the EMG
during this phase appear to be central in origin. Since the
first significant effect was obtained after i.c.v. administra-
tion (Fig 7H) it is possible that supraspinal effects pre-
dominate with spinal sites contributing.
The EMG during phase 3 (closing phase) of the contrac-
tion was decreased only after the highest dose of clozapine
(50 nmoles) i.c.v. (Fig 6C). This dose was still 14×  smaller
than the first significant dose i.v. and therefore a central
effect of clozapine is probable.
Finally, the amplitude of the individual bursts of EMG re-
corded from the external urethral sphincter during phase
2 of the contraction also decreased after clozapine i.t. or
i.c.v. (Fig 6D). Since the doses that yielded significant re-
ductions were smaller than those observed after i.v. adm-
nistration, a central effect is likely. Moreover, since 5
nmoles of clozapine i.t. produced a significant reduction
when compared to the same dose i.c.v., a spinal effect of
clozapine in mediating the reduction of the burst ampli-
tude of the EMG is possible.
In the anesthetized rat, the external urethral sphincter
contracts and relaxes during the expulsion phase in a
manner that is complimentary to the high frequency oscil-
lations observed in the bladder pressure record [19]
whereas in humans the external sphincter not active dur-
ing voiding. Pharmacological blockade of the external
urethral sphincter in the rat resulted in decreased micturi-
tion volume and increased residual volume [20–23] sug-
gesting that the activity of the external urethral sphincter
contributes to efficient voiding in the rat. Therefore, cen-
tral administration of clozapine, by reducing the activity
of the EUS, contributes to the decrease in voiding efficien-
cy by reducing micturition volume and increasing residual
volume.
Alpha1 adrenergic antagonists have been shown to inhibit
pudendal reflexes in anesthetized cats [24–26]. However,
a systemic dose of prazosin (alpha1 antagonist) did not
inhibit the EUS EMG activity during high frequency oscil-
lations in the rat [27]. Thus, although alpha1 antagonism
has been shown to modulate pudendal reflexes in the cat,
their role in modulating the activity of the EUS during
micturition in the rat appears unclear.
In summary, our results in the present experiments sug-
gest that most of the effects of clozapine on urodynamic
parameters can be ascribed to central effects. Expulsion
parameters, such as micturition volume, residual volume,
expulsion time, and amplitude of the high-frequency os-
cillations, appear to be mediated by the central action
(spinal or supraspinal) of clozapine. The activity of the
EUS also appears to decrease after central application of
clozapine. Therefore, central effects of clozapine appear to
decrease the voiding efficiency of the bladder in the rat.
Contraction time clearly showed a peripheral effect only,
whereas changes in bladder capacity were difficult to ex-
plain from central effects and probably reflect peripheral
effects of clozapine.
Clozapine is metabolized mainly at the liver resulting in
several metabolites [5,14]. One of the major metabolites,
N-desmethylclozapine has been shown to have pharma-
cological activity both in vitro [28] and in vivo in rats [29].
In addition, N-desmethylclozapine is found in large con-
centrations in the serum of schizophrenic patients [5,15]
and in rats [30]. The contribution of N-desmethylclozap-
ine to clozapine's central effects has been questioned re-
cently, since the levels of N-desmethylclozapine in the
brain were much lower than those of clozapine [30] sug-
gesting that N-desmethylclozapine does not cross the
blood-brain barrier as readily as clozapine. Since we ob-
served effects from central application of clozapine, we
consider it unlikely that the effects of metabolites contrib-
uted significantly. However, whether any of the major
clozapine metabolites also have a role in regulating mic-
turition remains to be determined.
Conclusions
Atypical neuroleptics are useful in treating patients that
are refractory to "traditional" antipsychotic medication
and produce fewer extrapyramidal side effects. However,
other side effects still occur with varying severity and fre-
quency [31] and continue to pose a challenge to effective
treatment. Urinary disturbances as a result of clozapine
therapy have been well documented, and include inconti-BMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/6
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nence, enuresis and urgency [4,5,32]. Other atypical an-
tipsychotics, such as risperidone [7] and olanzapine [10]
have been reported to produce urinary incontinence.
We have previously shown [11–13] that systemic admin-
istration of clozapine, olanzapine and risperidone to an-
esthetized rats reduced voiding efficiency. Risperidone
had smaller maximal effects than olanzapine and clozap-
ine and had no direct (peripheral) inhibitory effects on
the amplitude of bladder contractions. In the present
study we show that clozapine acts at supraspinal and spi-
nal sites to inhibit certain urodynamic parameters and the
external urethral sphincter of the rat resulting in decreased
voiding efficiency.
If these effects also occur in patients, they may contribute
to the urinary disturbances reported following clozapine
therapy. The exact receptor types (or combination of re-
ceptor types) responsible for clozapine's central effects on
micturition were not investigated in the present study.
However, isolating particular receptors that contribute to
the effects of clozapine might be useful in designing neu-
roleptics that may avoid these side effects or in providing
an adjunct therapy to relieve some of the side effects.
Materials and Methods
Surgical procedures
The experiments were conducted in compliance with the
USDA Animal Welfare Act and amendments thereto and
the revised Guide for the Care and use of Laboratory Ani-
mals DHEW (NIH) and were approved by the Animal
Studies Subcommittee of the Bay Pines Veterans Adminis-
tration Medical Center.
Surgical procedures have been described in detail else-
where [12]. Rats (female Sprague-Dawley; n = 16; 230–
270 g; Harlan; IN) were anesthetized with halothane and
placed on a heating pad. A catheter (PE-50) was intro-
duced into the jugular vein to administer urethane (1.1 g/
kg) over a period of 20 minutes while decreasing the level
of halothane to prevent respiratory depression. Rats were
instrumented with either an intrathecal cannula placed
over the L6/S1 spinal segment or a cannula into the right
lateral ventricle.
An incision was made over the dorsal aspect of the neck
and the overlying muscles were retracted to expose the at-
lanto-occipital membrane. An intrathecal catheter (PE 10)
was introduced through a small slit in the atlanto-occipi-
tal membrane and positioned over the L6/S1 spinal cord
segments [33]. Saline soaked gelfoam was placed around
the catheter and the neck muscles and skin were sutured.
Spinal segmental location of the catheter was verified
post-mortem by performing a laminectomy.
Following a small craniectomy, a stainless-steel cannula
(27 ga) was placed in the lateral ventricle at the following
coordinates: AP - 1.0, ML = 1.2; V= 3.2 mm [34]. The can-
nula was held in place with skull screws and dental acrylic.
At the end of the experiment, 5 µl of fast-green (1%) was
infused through the cannula while observing the CSF
though a small slit in the atlanto-occipital membrane. Al-
most immediate visualization of the fast-green in the
fourth ventricle was taken to indicate appropriate place-
ment of the cannula into the lateral ventricle.
After an abdominal incision, both ureters were tied distal-
ly and cut centrally and allowed to drain onto cotton
gauzes that were directed outside the animal. A catheter
(PE-90) was introduced into the bladder dome and tied in
place with a purse string suture. A catheter (PE-50) was in-
troduced into the right femoral artery for blood pressure
recording. Stainless-steel wires (0.003 in.; A-M Systems;
WA) insulated except at the tip were introduced into the
external urethral sphincter for EMG recording (DAM 50;
WPI; bandwidth= 3 to 3 kHz; gain: 1000–10,000).
Urodynamic studies
In pilot animals, the dose and duration of effects was de-
termined by administering clozapine (saline,
0.5,5,50,100 nmoles) at 10 min intervals either intrathe-
cally (n = 2) or intracerebroventricularly (n = 2) during
continuous cystometry (infusion rate = 0.11 ml/min)
while recording bladder pressure, external urethral
sphincter EMG, and blood pressure. Fifty (50) nmoles of
clozapine administered by either route resulted in a de-
crease in arterial pressure (mean decrease in MAP was 20
± 2 and 15 ± 3 mm Hg for intrathecal and intracerebrov-
entricular administration, respectively. The onset time
ranged from 1–1.5 min from the start of the infusion).
Since clozapine has alpha1 antagonist effects [2] it is pos-
sible that the blood pressure decreases were due to spread
of clozapine into the periphery following central adminis-
tration. Doses smaller than 50 nmoles did not elicit a
drop in arterial pressure. In addition, 50 nmoles repre-
sents a dose close to the smallest intravenous dose used
previously (0.1 mg/kg [12]). Therefore, during single
cystometry, the dose range was limited to 0.5 to 50
nmoles in order to reduce possible peripheral spread of
clozapine.
Single cystometry studies were conducted as follows. The
bladder was emptied and allowed to equilibrate to air
pressure for 5 minutes before beginning each cystometro-
gram. Room temperature saline was infused into the blad-
der (0.11 ml/min) while recording bladder pressure and
the infusion was stopped when a contraction occurred.
Volume expelled was determined by placing cotton gauze
at the urinary meatus and weighing before and after mic-
turition. External urethral sphincter EMG (EUS-EMG) wasBMC Pharmacology 2002, 2 http://www.biomedcentral.com/1471-2210/2/6
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recorded throughout the cystometrogram and for some
time after the filling had stopped. Increasing doses of cloz-
apine (Sigma, vehicle, 0.5, 5, 50 nmoles in a volume of 5
µl; followed by a 7 µl saline wash) were administered
through the intrathecal catheter (n = 6; Mean weight = 245
gm) or through the intracerebroventricular cannula (n =
6; Mean weight = 245 gm) at approximately 10-minute in-
tervals. Clozapine was dissolved in a minimal amount of
0.1 N hydrochloric acid, and brought up to volume with
saline (final pH = 6). Cystometrograms were started ap-
proximately 3 minutes after each drug administration. At
the end of the experiment the rat was euthanized with an
overdose of urethane (3.0 mg/kg; i.v.).
Data analysis
Bladder pressure, EUS-EMG and blood pressure during
the single cystometrograms were displayed in an electron-
ic chart recorder (RC Electronics; Goleta, CA) and ana-
lyzed off-line (Dataview, W.J. Heitler, U. St Andrews,
Scotland). The following parameters were examined from
the cystometrogram as described in detail earlier [12]:
bladder capacity (amount of fluid infused to elicit a con-
traction); micturition volume (amount of fluid expelled);
residual volume ([bladder capacity-micturition volume]/
[bladder capacity] × 100); pressure threshold (pressure at
which contraction begins); peak pressure (maximal pres-
sure during contraction); contraction time; expulsion
time (time between peak pressure and end of high fre-
quency oscillations); amplitude of high frequency oscilla-
tions. The EMG activity was examined by dividing the
bladder contraction into three phases in a modification of
the technique of Chien et al. [19] a contraction phase
(phase 1); an expulsion phase (phase 2) and a closing
phase (phase 3).
The raw EMG was rectified, integrated (0.5 second bin)
and the area under curve of the EMG corresponding to
each phase of the bladder contraction was measured (Sig-
ma Scan/Image; Jandel Scientiflcs, San Rafael, Ca). Drug
effects for the EMG were calculated as percent of control.
Values are presented as Mean + S.E.M. Repeated measures
ANOVA (GB Stat; Dynamic Microsystems; MD) were per-
formed on all parameters and when statistical significance
(p<0.05) was obtained, comparisons between control and
different drug dosages and between different routes (i.t.
vs. i.c.v.) were made using Fisher's protected t-test [35] .
List of Abbreviations
CMG = cystometrogram
EMG = electromyogram
EUS = external urethral sphincter
HFO = high frequency oscillations
i.c.v. = intracerebroventricular
i.t. = intrathecal
i.v. = intravenous
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